Sunday 11 October 2026
Export all VXRT data to Excel Powerpack
VAXART, INC.
VXRT Healthcare Biotechnology
VAXART, INC.’s revenue for fiscal 2025 (year ended December 2025) was $237.3 million, up 726.7% from fiscal 2024. In the quarter to June 2026, revenue fell 31.6%, EPS grew 14.3% and free cash flow grew 117.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
0.43
0.00
0.00%
Follow VXRT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 5.83 | 4.07 | 3.81 |
P/S ratio |
0.56 | 0.34 | 0.57 | 0.61 | |
P/FCF ratio |
0.00 | 10.64 | 9.92 | 4.42 | |
P/Operating CF |
31.76 | 2.63 | (71.47) | 53.18 | |
P/B ratio |
3.08 | 0.92 | 1.56 | 1.79 | |
Price to Tangible BV |
4.28 | 1.00 | 1.69 | 1.96 | |
EV/Sales |
0.37 | 0.08 | 0.34 | 0.35 | |
EV/EBITDA |
0.00 | 0.68 | 1.91 | 1.87 | |
EV/Operating CF |
(1.81) | 2.33 | 5.70 | 2.50 | |
EV/FCF |
(1.80) | 2.37 | 5.87 | 2.54 | |
Quick Ratio |
0.68 | 1.33 | 1.54 | 1.52 | |
Current Ratio |
0.69 | 1.57 | 1.71 | 1.60 | |
Net Debt/EBITDA |
5.17 | (1.12) | (9.77) | 5.11 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.79 | 1.35 | 1.51 | 1.48 | |
Operating CF/Net income |
(0.32) | 0.56 | (0.40) | (0.21) | |
Capex/Depreciation |
(0.05) | 0.00 | (0.42) | (0.04) | |
Interest Coverage |
(12.85) | 101.51 | 10.24 | (24.48) | |
Research and Development Expense of Revenue |
104.88% | 43.31% | 74.98% | 124.16% | |
Selling, General and Administrative Expense of Revenue |
5.91% | 3.52% | 11.83% | 24.29% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.04 | 0.04 | |
Share Based Compensation of Revenue |
2.79% | 1.65% | 3.78% | 4.75% | |
Graham Net Nets |
(0.79) | 0.47 | 0.31 | 0.23 | |
Graham Number |
0.00 | 0.72 | 1.15 | 1.11 | |
Earnings Yield |
(63.89%) | 17.14% | 24.59% | 26.23% | |
Free Cash Flow Yield |
(36.98%) | 9.40% | 10.08% | 22.61% | |
Revenue per Share |
0.32 | 0.45 | 0.16 | 0.11 | |
Operating CF per Share |
0.01 | 0.13 | (0.01) | 0.01 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.01 | 0.13 | (0.01) | 0.01 | |
Cash per Share |
0.13 | 0.28 | 0.25 | 0.26 | |
Shareholders Equity per Share |
0.12 | 0.38 | 0.39 | 0.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.12 | 0.38 | 0.39 | 0.34 | |
Free Cash Flow |
2.48 | 30.66 | (2.50) | 2.75 | |
Working Capital |
(51.93) | 49.37 | 54.86 | 43.58 | |
Capital Expenditures |
(0.11) | 0.00 | (0.44) | (0.02) | |
Net Current Asset Value |
(64.86) | 37.84 | 45.77 | 33.88 | |
EV/EBIT |
0.00 | 0.99 | 2.28 | 2.14 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 4.46 | 3.84 | 3.73 | |
| Other line items | |||||
Average Receivables |
44.81 | 31.66 | 36.85 | 44.03 | |
Average Payables |
27.80 | 14.23 | 20.40 | 13.79 | |
Average Assets |
187.83 | 176.23 | 169.31 | 164.64 | |
Average Common Equity |
47.60 | 73.36 | 69.87 | 57.62 |
Columns are period end dates